Triodos Investment Management BV Has $36.24 Million Position in Elevance Health, Inc. $ELV

Triodos Investment Management BV lessened its holdings in Elevance Health, Inc. (NYSE:ELV) by 5.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 93,180 shares of the company’s stock after selling 5,550 shares during the period. Elevance Health makes up 2.7% of Triodos Investment Management BV’s portfolio, making the stock its 14th biggest position. Triodos Investment Management BV’s holdings in Elevance Health were worth $36,243,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. CWA Asset Management Group LLC acquired a new position in Elevance Health in the first quarter worth about $299,000. Focus Partners Wealth raised its position in Elevance Health by 4.6% in the first quarter. Focus Partners Wealth now owns 22,446 shares of the company’s stock worth $9,764,000 after purchasing an additional 982 shares in the last quarter. Dynamic Advisor Solutions LLC raised its position in Elevance Health by 11.3% in the second quarter. Dynamic Advisor Solutions LLC now owns 8,034 shares of the company’s stock worth $3,125,000 after purchasing an additional 817 shares in the last quarter. GAMMA Investing LLC raised its position in Elevance Health by 88.1% in the first quarter. GAMMA Investing LLC now owns 3,390 shares of the company’s stock worth $1,475,000 after purchasing an additional 1,588 shares in the last quarter. Finally, Asio Capital LLC increased its holdings in shares of Elevance Health by 7.1% during the second quarter. Asio Capital LLC now owns 15,371 shares of the company’s stock worth $5,979,000 after buying an additional 1,015 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Price Performance

Shares of ELV stock opened at $358.24 on Friday. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $510.24. The stock has a market cap of $80.67 billion, a PE ratio of 15.24, a PEG ratio of 1.32 and a beta of 0.59. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The firm’s 50 day moving average price is $313.51 and its two-hundred day moving average price is $359.66.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Thursday, July 17th. The company reported $8.84 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $9.30 by ($0.46). Elevance Health had a net margin of 2.83% and a return on equity of 17.59%. The business had revenue of $49.42 billion during the quarter, compared to the consensus estimate of $48.26 billion. During the same period in the previous year, the business posted $10.12 earnings per share. Elevance Health’s revenue was up 14.3% compared to the same quarter last year. As a group, analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 25th. Shareholders of record on Wednesday, September 10th were issued a $1.71 dividend. The ex-dividend date was Wednesday, September 10th. This represents a $6.84 annualized dividend and a yield of 1.9%. Elevance Health’s dividend payout ratio (DPR) is 29.11%.

Analysts Set New Price Targets

Several analysts have recently weighed in on ELV shares. Argus reaffirmed a “hold” rating on shares of Elevance Health in a report on Monday, July 21st. Wall Street Zen lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Friday, July 18th. Leerink Partners reaffirmed a “market perform” rating and set a $310.00 price objective (down previously from $510.00) on shares of Elevance Health in a report on Friday, July 18th. Morgan Stanley decreased their price target on shares of Elevance Health from $428.00 to $316.00 and set an “overweight” rating on the stock in a research note on Friday, July 18th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Elevance Health from $472.00 to $384.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 22nd. Twelve analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $414.63.

Insider Buying and Selling at Elevance Health

In other news, Director Susan D. Devore bought 1,200 shares of the business’s stock in a transaction on Tuesday, August 19th. The shares were bought at an average cost of $312.15 per share, for a total transaction of $374,580.00. Following the completion of the acquisition, the director owned 3,502 shares in the company, valued at approximately $1,093,149.30. This trade represents a 52.13% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Gail Boudreaux bought 8,500 shares of the business’s stock in a transaction on Friday, July 18th. The stock was purchased at an average price of $286.94 per share, for a total transaction of $2,438,990.00. Following the completion of the acquisition, the chief executive officer owned 151,020 shares of the company’s stock, valued at approximately $43,333,678.80. This trade represents a 5.96% increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.29% of the company’s stock.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.